Synopsis
Synopsis
0
EU WC
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anexate
2. Flumazepil
3. Lanexat
4. Ro 15 1788
5. Ro 15-1788
6. Ro 151788
7. Romazicon
1. 78755-81-4
2. Anexate
3. Flumazepil
4. Romazicon
5. Lanexat
6. Mazicon
7. Ro 15-1788
8. Fumazenil
9. Flumazenilum [latin]
10. Flumazenilo [spanish]
11. Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate
12. Flumazenilo
13. Flumazenilum
14. Ro-15-1788
15. [11c]flumazenil
16. Flumazenil (ro 15-1788)
17. Ro 151788
18. Ethyl 8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
19. Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
20. Chembl407
21. Nsc-759193
22. Ro15-1788
23. Mls000028850
24. Ro-151788
25. Chebi:5103
26. 4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic Acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, Ethyl Ester
27. Ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate
28. Ro 15-1788/000
29. Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
30. 40p7xk9392
31. Ro-1722
32. Ncgc00015439-06
33. Smr000058450
34. Ro-151788000
35. Ro-41-8157
36. Dsstox_cid_3064
37. Ro-15-1788/000
38. Dsstox_rid_76860
39. Dsstox_gsid_23064
40. Flumazil
41. [3h]ro15-1788
42. Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
43. Cas-78755-81-4
44. Sr-01000075879
45. Brn 4763661
46. Flumenazil
47. Flunarizin
48. Roma
49. [11c]flumazenil (pet Ligand)
50. Unii-40p7xk9392
51. Flumazenil [usan:usp:inn:ban]
52. Romazicon (tn)
53. Flumazenil Authentic
54. Fyp
55. Flumazenil- Bio-x
56. Mfcd00242764
57. Tocris-1328
58. Flumazenil [mi]
59. Flumazenil [inn]
60. Flumazenil [jan]
61. Opera_id_1516
62. Flumazenil [usan]
63. Lopac-f-6300
64. Flumazenil [vandf]
65. Biomol-nt_000285
66. Upcmld-dp137
67. Flumazenil [mart.]
68. Ethyl 8-fluoro-5-methyl-5,6-dihydro-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
69. Flumazenil [usp-rs]
70. Flumazenil [who-dd]
71. Lopac0_000506
72. Schembl79030
73. Flumazenil (jan/usp/inn)
74. Mls000759529
75. Mls001076354
76. Mls001424108
77. Bidd:gt0766
78. Bpbio1_001190
79. Gtpl4192
80. Gtpl4367
81. Zinc1464
82. Dtxsid2023064
83. Flumazenil [orange Book]
84. Upcmld-dp137:001
85. Bdbm26263
86. Flumazenil [ep Monograph]
87. Flumazenil [usp Monograph]
88. Hms2051d17
89. Hms2089b15
90. Hms2234f06
91. Hms3261f13
92. Hms3267p09
93. Hms3374e10
94. Hms3393d17
95. Hms3412g20
96. Hms3657k11
97. Hms3676g20
98. Hms3884g11
99. Pharmakon1600-01505701
100. Afc-3002
101. Amy39505
102. Bcp07573
103. Hy-b0009
104. Flumazenil, >99% (hplc), Solid
105. Tox21_110148
106. Tox21_500506
107. Nsc759193
108. Pdsp1_001778
109. Pdsp2_001761
110. S1332
111. Akos015888159
112. Tox21_110148_1
113. Ac-6846
114. Ccg-100968
115. Cs-0629
116. Db01205
117. Lp00506
118. Nc00218
119. Nsc 759193
120. Sdccgsbi-0050490.p003
121. Ncgc00015439-01
122. Ncgc00015439-02
123. Ncgc00015439-03
124. Ncgc00015439-04
125. Ncgc00015439-05
126. Ncgc00015439-07
127. Ncgc00015439-08
128. Ncgc00015439-09
129. Ncgc00015439-11
130. Ncgc00015439-14
131. Ncgc00015439-22
132. Ncgc00025116-01
133. Ncgc00025116-02
134. Ncgc00025116-03
135. Ncgc00025116-04
136. Ncgc00025116-05
137. Ncgc00261191-01
138. As-13923
139. Bf164469
140. Flumazenil 100 Microg/ml In Acetonitrile
141. Sbi-0050490.p002
142. Db-056331
143. Eu-0100506
144. F-145
145. F0958
146. Ft-0630863
147. Sw197598-2
148. C07825
149. D00697
150. F 6300
151. Ab00572626-12
152. Ab00572626-13
153. Ab00572626_14
154. Ab00572626_15
155. 755f814
156. A839484
157. Q421920
158. Q-201122
159. Sr-01000075879-1
160. Sr-01000075879-3
161. Sr-01000075879-7
162. Brd-k98769987-001-01-3
163. Brd-k98769987-001-12-0
164. Z1551429735
165. Flumazenil, United States Pharmacopeia (usp) Reference Standard
166. Ethyl 8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate.
167. 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic Acid Ethyl Ester
168. 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic Acid, Ethyl Ester
169. 8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic Acid Ethyl Ester
170. Ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),3,5,10,12-pentaene-5-carboxylate
171. Ethyl 8-fluoranyl-5-methyl-6-oxidanylidene-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
172. Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylate
173. Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepin-3-carboxylate
174. Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate #
Molecular Weight | 303.29 g/mol |
---|---|
Molecular Formula | C15H14FN3O3 |
XLogP3 | 1 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 3 |
Exact Mass | 303.10191948 g/mol |
Monoisotopic Mass | 303.10191948 g/mol |
Topological Polar Surface Area | 64.4 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 461 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Flumazenil |
PubMed Health | Flumazenil (Injection) |
Drug Classes | Toxicology-Antidote Agent |
Drug Label | ROMAZICON (flumazenil) is a benzodiazepine receptor antagonist. Chemically, flumazenil is ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a](1,4) benzodiazepine-3-carboxylate. Flumazenil has an imidazobenzodiazepine structure, a calculated... |
Active Ingredient | Flumazenil |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.5mg/5ml (0.1mg/ml); 1mg/10ml (0.1mg/ml) |
Market Status | Prescription |
Company | Hikma Farmaceutica; Sandoz; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms; Bedford Labs; Agila Speclts |
2 of 2 | |
---|---|
Drug Name | Flumazenil |
PubMed Health | Flumazenil (Injection) |
Drug Classes | Toxicology-Antidote Agent |
Drug Label | ROMAZICON (flumazenil) is a benzodiazepine receptor antagonist. Chemically, flumazenil is ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a](1,4) benzodiazepine-3-carboxylate. Flumazenil has an imidazobenzodiazepine structure, a calculated... |
Active Ingredient | Flumazenil |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.5mg/5ml (0.1mg/ml); 1mg/10ml (0.1mg/ml) |
Market Status | Prescription |
Company | Hikma Farmaceutica; Sandoz; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms; Bedford Labs; Agila Speclts |
For the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures.
FDA Label
Flumazenil antagonizes the CNS effects produced by benzodiazepines, but does not antagonize the central nervous system effects of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (including ethanol, barbiturates, or general anesthetics) and does not reverse the effects of opioids.
Antidotes
Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AB - Antidotes
V03AB25 - Flumazenil
Route of Elimination
Flumazenil is completely (99%) metabolized. Elimination of radiolabeled drug is essentially complete within 72 hours, with 90% to 95% of the radioactivity appearing in urine and 5% to 10% in the feces.
Volume of Distribution
0.9 to 1.1 L/kg
Clearance
1 L/hr/kg [healthy volunteers receiving a 5-minute infusion of a total of 1 mg]
Hepatic. Flumazenil is completely (99%) metabolized. The major metabolites of flumazenil identified in urine are the de-ethylated free acid and its glucuronide conjugate.
Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).
Flumazenil, an imidazobenzodiazepine derivative, is a benzodiazepine antagonist. It competitively inhibits the benzodiazepine binding site on the GABA/benzodiazepine receptor complex. Flumazenil is a weak partial agonist in some animal models of activity, but has little or no agonist activity in man.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
65
PharmaCompass offers a list of Flumazenil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Flumazenil manufacturer or Flumazenil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Flumazenil manufacturer or Flumazenil supplier.
PharmaCompass also assists you with knowing the Flumazenil API Price utilized in the formulation of products. Flumazenil API Price is not always fixed or binding as the Flumazenil Price is obtained through a variety of data sources. The Flumazenil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DSSTox_CID_3064 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DSSTox_CID_3064, including repackagers and relabelers. The FDA regulates DSSTox_CID_3064 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DSSTox_CID_3064 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DSSTox_CID_3064 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DSSTox_CID_3064 supplier is an individual or a company that provides DSSTox_CID_3064 active pharmaceutical ingredient (API) or DSSTox_CID_3064 finished formulations upon request. The DSSTox_CID_3064 suppliers may include DSSTox_CID_3064 API manufacturers, exporters, distributors and traders.
click here to find a list of DSSTox_CID_3064 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DSSTox_CID_3064 DMF (Drug Master File) is a document detailing the whole manufacturing process of DSSTox_CID_3064 active pharmaceutical ingredient (API) in detail. Different forms of DSSTox_CID_3064 DMFs exist exist since differing nations have different regulations, such as DSSTox_CID_3064 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DSSTox_CID_3064 DMF submitted to regulatory agencies in the US is known as a USDMF. DSSTox_CID_3064 USDMF includes data on DSSTox_CID_3064's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DSSTox_CID_3064 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DSSTox_CID_3064 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DSSTox_CID_3064 Drug Master File in Japan (DSSTox_CID_3064 JDMF) empowers DSSTox_CID_3064 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DSSTox_CID_3064 JDMF during the approval evaluation for pharmaceutical products. At the time of DSSTox_CID_3064 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DSSTox_CID_3064 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a DSSTox_CID_3064 Drug Master File in Korea (DSSTox_CID_3064 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DSSTox_CID_3064. The MFDS reviews the DSSTox_CID_3064 KDMF as part of the drug registration process and uses the information provided in the DSSTox_CID_3064 KDMF to evaluate the safety and efficacy of the drug.
After submitting a DSSTox_CID_3064 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DSSTox_CID_3064 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of DSSTox_CID_3064 suppliers with KDMF on PharmaCompass.
A DSSTox_CID_3064 CEP of the European Pharmacopoeia monograph is often referred to as a DSSTox_CID_3064 Certificate of Suitability (COS). The purpose of a DSSTox_CID_3064 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DSSTox_CID_3064 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DSSTox_CID_3064 to their clients by showing that a DSSTox_CID_3064 CEP has been issued for it. The manufacturer submits a DSSTox_CID_3064 CEP (COS) as part of the market authorization procedure, and it takes on the role of a DSSTox_CID_3064 CEP holder for the record. Additionally, the data presented in the DSSTox_CID_3064 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DSSTox_CID_3064 DMF.
A DSSTox_CID_3064 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DSSTox_CID_3064 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DSSTox_CID_3064 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DSSTox_CID_3064 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DSSTox_CID_3064 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DSSTox_CID_3064 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DSSTox_CID_3064 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DSSTox_CID_3064 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DSSTox_CID_3064 suppliers with NDC on PharmaCompass.
DSSTox_CID_3064 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DSSTox_CID_3064 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DSSTox_CID_3064 GMP manufacturer or DSSTox_CID_3064 GMP API supplier for your needs.
A DSSTox_CID_3064 CoA (Certificate of Analysis) is a formal document that attests to DSSTox_CID_3064's compliance with DSSTox_CID_3064 specifications and serves as a tool for batch-level quality control.
DSSTox_CID_3064 CoA mostly includes findings from lab analyses of a specific batch. For each DSSTox_CID_3064 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DSSTox_CID_3064 may be tested according to a variety of international standards, such as European Pharmacopoeia (DSSTox_CID_3064 EP), DSSTox_CID_3064 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DSSTox_CID_3064 USP).